Jay Alexander Moore
Computational biology • Cancer genomics • Neurodegeneration
Interests
Interdisciplinary researcher studying data and genomics in human health. My best experiences have had these in common:
- Hands on work with the latest technology
- Working with engaged and excited people
- Learning about the complex biology that drives our lives
Positions
- Oct 2025–present UKDRI • Imperial College London Research Assistant @ Neurogenomics Lab
- 2025 University College London MSc, Personalised Medicine and Novel Therapies (Distinction)
- Oct 2022–Mar 2025 Curileum Discovery Ltd Biomedical Scientist • Drug discovery startup
- Jul 2018–Jul 2022 Foundation Medicine Inc. Scientist I / Senior Research Associate / Research Associate $5.3B acquisition by Roche
Publications
- Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-ribose) polymerase inhibitor response
- A novel HRD signature is predictive of FOLFIRINOX benefit in metastatic pancreatic cancer
- Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis
- Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation
- The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling
- Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response
- Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing
- Genomic profiling of combined hepatocellular cholangiocarcinoma reveals genomics similar to either hepatocellular carcinoma or cholangiocarcinoma
- The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling
- Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations
- Poor prognosis among radiation-associated bladder cancer is defined by clinicogenomic features